Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
Ticker SymbolACOG
Company nameAlpha Cognition Inc
IPO dateJun 09, 2021
CEOMcfadden (Michael E)
Number of employees52
Security typeOrdinary Share
Fiscal year-endJun 09
Addressc/o 1200 - 750 West Pender Street
CityVANCOUVER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeV6C 2T8
Phone16045649244
Websitehttps://www.alphacognition.com/
Ticker SymbolACOG
IPO dateJun 09, 2021
CEOMcfadden (Michael E)
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data